Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Low-Cost Technology Diagnoses Influenza Early

By LabMedica International staff writers
Posted on 25 Sep 2013
A novel technology is showing promise as the basis for a much-needed home test to diagnose influenza quickly, before the window for taking antiviral drugs closes. More...


A fast, inexpensive diagnostic test, similar to the quick throat swabs for Streptococcus pneumoniae tests, is especially important for influenza, which causes widespread illness and an average of 36,000 deaths annually in the USA alone.

A scientist at the Georgia State University (Atlanta, GA, USA) and a colleague at the University of Cincinnati (OH, USA) launched a search for a fundamental approach for diagnosing influenza and other viral disease because of drawbacks with existing tests. Those tests can produce results in about 15 minutes. However, they are expensive and sometimes give false negative results when the patient is infected with the influenza virus.

The influenza viruses have two major antigens, hemagglutinin and neuraminidase, which determine the specific strain of the virus. Changes in hemagglutinin and/or new combinations of hemagglutinin and neuraminidase signal the emergence of a new strain of virus. The novel technology uses various forms of carbohydrates that can capture the hemagglutinin and neuraminidase, and via a color change or other signal, indicate both infection and the specific type or strain of influenza virus. Information on the strain would be important, enabling doctors to pick the most effective antiviral drug. The innovative approach has other potential advantages, including quicker results, lower cost, and greater reliability.

Influenza binds to N-acetyl neuraminic acid or sialic acid present on the surface of cells. The investigators are developing robust synthetic analogs of sialic acids that can be used as capture and reporter molecules in point of care diagnostics. The synthesis, stability and the ability of these molecules to capture influenza virus at room temperature without the addition of inhibitors was the crux of the technology. The approach so far is living up to expectations, with laboratory experiments verifying that it can detect influenza viruses. The team of Suri Iyer, PhD, and Allison Weiss, PhD, plan to move ahead in the autumn with tests on samples taken from human volunteers. The study was presented at the 246th National Meeting & Exposition of the American Chemical Society held September 8-12, 2013 in Indianapolis (IN, USA).

Related Links:

Georgia State University
University of Cincinnati



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.